Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CES 2022: Defying Omicron, World’s Biggest Tech Show Goes Live In Las Vegas

Executive Summary

CES 2022 is missing some marquee names due to the coronavirus surge, but there’s still plenty to take in at the intersection of digital health and consumer tech. In this roundup, Medtech Insight highlights some standouts, with commentary from company leaders.

You may also be interested in...



Roundup: AI-Powered Assistive Hearing Devices Scream With Personalization; Femtech From Baby Makers To Menopause

In this first of a two-part roundup from CES, Medtech Insight tunes into two companies that developed assistive hearing devices, OrCam Hear and Concha Labs, and three women’s health companies focusing on menopausal symptoms and an app to track the “baby-making” journey. 

Kintsugi’s AI Software Analyzes Voice For Signs Of Depression, Anxiety

Kintsugi is developing an AI-driven software that analyzes voice to detect depression and anxiety, offering clinicians an early screening tool in call centers, telehealth and remote monitoring.

CES 2023 Turnout Will Double Last Year’s; AARP AgeTech Takes Center Stage

CES 2023 will be dedicating two days of programming to digital health, and AARP will be featuring 18 start-ups, panel discussions, programming, and pitching events.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel